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Available online 19 October 2016Objective: Highlight a complete molar pregnancy with possible complications and pertinent clinical information
to aid doctors in recognizing the disease quickly to provide treatment to limit adverse outcomes.
Context: Completemolar pregnancy is rare and compromises 1:500–1:2000 pregnancies [1-4]. As technology has
improved, the presentation of complete molar pregnancy has changed [1,5-6].
Summary: A 19-year old African American female presented to the emergency room (ER) three times within
14 days for abdominal pain. A pregnancy test was positive and on the third visit quantitative β-human chorionic
gonadotropin (HCG) was elevated without signs of an intrauterine pregnancy (IUP). Dilation and curettage
(D&C) was done with small perforation of the uterus. Pathology report indicated a complete molar pregnancy.
The patient failed to follow-up and returned to ER 22 days later where an abdominal mass was found prompting
surgery. Hematomas and abdominal adhesions were removed and again pathology showed a complete molar
pregnancy. Follow-up HCG levels failed to decrease appropriately so the patient was referred to oncology
where metastatic choriocarcinoma of the liver was diagnosed. Chemotherapy was initiated and HCGmonitored.
Patient was readmitted for infections and complications, but did eventually have her HCG return to zero.
Data sources: Clinical Key, Purdue Library, and UpToDate were used to search for literature.
Conclusion: Prompt recognition of a completemolemay lead to a less extensive disease process. Presentation has
recently changed so it is important to know signs. Patient compliance likely results in fewer complications and
costs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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β-HCG1. Introduction
This case report highlights a complete molar pregnancy with some
possible complications and its pertinent clinical information to aide ob-
stetrics and gynecology (OB/GYN) doctors in appropriately recognizing
the disease early in order to quickly provide treatment to prevent ad-
verse outcomes. Current literature on a complete molar pregnancy is
reviewed with the case. A molar pregnancy is one in which an extra
set of paternal chromosomes fertilize an egg with no genetic material
or also called an empty egg [1–3]. Two variations of molar pregnancy
are known; complete (diploid) and partial (triploid) [1–2,4]. This case
study describes a complete molar pregnancy, how it may present, the
diagnosis, the treatment, andwhy it is important for the early identiﬁca-
tion of this condition.n, NC 28358, United States.
ood St, Spartanburg, SC 29303,
This is an open access article under th1.1. Incidence and Epidemiology
Complete molar pregnancies are thought to occur in 1:500–1:2000
pregnancies [1–4]. The majority of them, 90%, are from a single male
sperm with a diploid genome (46XX) [3,7]. Once the empty egg is acti-
vated by the sperm, no zygote forms. Instead, colonic villi turn into
grape like vesicles [3,6]. The exact cause is not known, but the incidence
appears to have a bimodal age distribution for those in their teens and
those between 40 and 50 years old [1,3]. African American females
have a higher chance of having a completemolar pregnancy andmortal-
ity from it [8]. Previousmolar pregnancy increases incidence 20–40× as
does intermarriage [2–3]. A diagnosis of complete mole gives 15–28%
chance of developing persistent disease and need for chemotherapy,
but this decreases to 1.1% if HCG reaches 50 IU/L any time after evacua-
tion of the pregnancy [4,9].
1.2. Signs and Symptoms and Diagnosis
Technology such as the ultrasound (US) and turnaround time on lab
tests have changed how one presents with a completemolar pregnancy
[5]. Whereas enlarged uterus, anemia, preeclampsia, hyperthyroidism,e CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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seems to be vaginal bleeding in as many as 84% of cases [5–6]. In the
1960s–70s, 97% of patientswould experience vaginal bleeding, 54% ane-
mia, 51% enlarged uterus, 27% pre-eclampsia, 26% hyperemesis, with
virtually all patients experiencing some symptoms [1,5–6]. In 1996–
2006, 81% of patients experienced vaginal bleeding, 13.9% anemia,
33.9% enlarged uterus, 2.2% pre-eclampsia, 30% hyperemesis, with
19.1% being completely asymptomatic [1,5–6]. An US can be ordered if
a pregnant women has any signs or symptoms that may cause concern
[3,6]. A completemolemay appear as a “snow storm” pattern on US due
to the villi which appear like vesicles [1,3,6]. In addition, serum HCG
should be measured and number compared to the standard values for
weeks of gestation as it is really the best test for diagnosing and follow-
ing a completemole [10]. If an HCG continues to increase past 14weeks
and at any time reaches a level of onemillion, this should cause concern
for a complete molar pregnancy [3]. The higher the HCG, the higher the
chance for more severe disease [6,9–10].
1.3. Treatment and Follow-up
If amolar pregnancy is suspected, a D&C should take place as soon as
possible and the HCG followed to prevent a major adverse outcome,
choriocarcinoma [1,3]. Choriocarcinoma is rare, occurring in only one
in 20,000–40,000with 50% of those in amolar pregnancy [1,3,8]. It com-
monly metastasizes to lungs, liver, brain, kidney, and gastrointestinal
tract [1]. The goal is to have a zero HCG within 8–12 weeks following
D&C [3]. In order to ensure this, it is recommend that HCG be followed
every one to two weeks until it reaches zero and then every one to
two months for six to twelve months for a total of six months after it
has gone to zero [3,10–12]. Several studies have questioned the necessi-
ty to have theHCG followed so strictly and if it is even necessary for HCG
to reach zero [4,9]. If the HCG decreases to zero then no treatment is
needed and the patient is considered cured, but one should avoid preg-
nancy for a year [4,10]. If a patient does become pregnant before a year
after having the HCG return to zero from amolar pregnancy, it can con-
tinue with close follow-up [12]. If the HCG does not decrease to zero,
then chemotherapy is warranted [8]. Chemotherapy regimens and pro-
tocols vary depending on physician preference, but some of the com-
mon drugs used either alone or together include methotrexate,
dactinomycin, etoposide, vincristine, and cyclophosphamide [1]. Treat-
ment success rate is generally high and the condition is easier to elimi-
nate if found early [10,13].
2. Methods
A literature searchwas performedusing Clinical Key, PurdueUniver-
sity Online Library, PubMed, and UpToDate. A total of 13 articles were
obtained from 1994 to 2013. Terms used for the search included “com-
plete molar pregnancy,” “choriocarcinoma,” and its corresponding clin-
ical features, as well as the presentation of the patient in the case study.
The most relevant articles were selected upon reading full article.
3. Presentation of Case
A 19-year old African American female, with past medical history of
only genital herpes, presented to the emergency room (ER) multiple
times within six weeks for abdominal pain. During the ﬁrst visit on
12/12/13, she had 8/10 abdominal pain and a distended abdomen. A
pregnancy test was found to be positive, but the patient declined an ul-
trasound (US) and no β-human chorionic gonadotropin (HCG) level
was obtained. She was diagnosed with constipation and pregnancy
with an unknown last menstrual period date. On the second ER visit
ten days later, she was found to have a HCG level of 60,638 IU/L. The pa-
tientwas discharged againwithout anUS. Three days later, on 12/25/13,
she again returned to the ER for the pain and allowed for an US which
did not show any IUP even though her HCG level was 100,606 IU/L.She was told to follow up with her obstetrician/gynecologist (OB/
GYN) doctor because of a likely abnormal pregnancy. She followed up
with her OB/GYN doctor the next day and again an US showed no intra-
uterine pregnancy (IUP). A dilation and curettage (D&C) was scheduled
for the next day, 12/27/13, and aHCG of 115,795 IU/Lwas found prior to
the procedure. A D&Cwas performed using suction with nomajor com-
plications, but there was a small perforation of the posterior uterus. Pa-
thology showed a complete hydatidiform mole. The patient failed to
show for a 2-week follow-up and returned to ER 1/18/14 with abdomi-
nal pain. An abdominal mass was found on US that prompted emergen-
cy surgery. Several hematomas and abdominal adhesions were found
and a drain was placed. Following surgery, a chest x-ray was found to
be negative. When the pathology returned several days later it showed
the hematomamimicked the D&C pathology, a complete mole. Post-op
HCG values (Table 1) originally started to decrease, and then started to
increase again so thepatientwas referred to oncology for further assess-
ment and the possibility of metastatic choriocarcinoma.
When the patient arrived to her ﬁrst appointment with the oncolo-
gist four days later, she had a computed tomography (CT) of the abdo-
men and pelvis and was given a prescription for contraceptive pills.
The CT scan showed liver metastasis and conﬁrmed the patient did
have metastatic choriocarcinoma. On follow-up for her CT scan results
she appeared sick so was admitted to the hospital. She had severe
right upper quadrant pain with nausea and vomiting, but denied any
other symptoms. On admission to the hospital (laparoscopy post-op
day 12), she had hemoglobin 8.6 g/dL, hematocrit 0.263 proportion of
1.0, platelets 323 × 109/L, basic metabolic panel (BMP) was unremark-
able except for glucose of 7.83 mmol/L, white blood cell count (WBC)
12.4 × 109/L, and HCG of 40,610 (see table 5 for normal values). She
had a negative abdominal X-ray, and magnetic resonance imaging
(MRI) showed liver metastasis. Due to concern for pelvic abscesses
and sepsis, blood cultures were taken (negative) and the patient was
started on antibiotics (clindamycin and piperacillin-tazobactam), as
well as oxycodone, and IV ﬂuids normal saline 0.9%. On the second hos-
pital day, thepatient reported feelingweak and lightheaded. Thepatient
was found to be orthostatic and labs showed hemoglobin 4.3 g/dL, he-
matocrit 0.129 proportion of 1.0, and platelets 84 × 109/L. The patient
was rushed to the ICU to be stabilized and transfused. She had another
CT scan which revealed ﬂuid in the pelvis that was thought to be due
to a bleed. She underwent emergency surgery where it was discovered
she was hemorrhaging from her liver at segment VIII and diaphragm.
The segment was debulked, and the patient was coagulated with pack-
ing, continued on the antibiotics and had several transfusions (six units
of packed red blood cells, two units of fresh frozen plasma, and two
units of platelets). On the third hospital day, she was started on multi-
agent chemotherapy (MAC) consisting of methotrexate, dactinomycin,
and cyclophosphamide for ﬁve days.
She successfully completed 1 cycle of MAC as an inpatient with no
infections so antibiotics were stopped and a port was placed so that
she could have MAC as an outpatient. She was discharged eight days
after being admitted to the hospital with a hemoglobin 9.2 g/dL, plate-
lets 141 × 109/L, and liver function tests ranging from 200 to 300. She
was injected with Depo-Provera, to prevent pregnancy as she had not
yet started her oral contraceptive pills. She was discharged with
hydrocodone bitartrate/acetaminophen, ibuprofen, docusate, and fer-
rous sulfate as well as instructions when to seek immediate medical at-
tention, and a follow-up appointment.
Nine days later on 2/3/14, the patient presented to the ER with a
fever N 38.8 °C, a runny nose, lower back pain, and right inguinal pain.
She denied any other symptoms and stated her family was sick with a
similar illness and that she had not received the ﬂu shot for the year.
Shewas admitted and had labs drawn (Table 2), chest X-ray (negative),
urine analysis (showed a trace of blood), blood cultures (negative), and
started on piperacillin/tazobactam, potassium, as well as ﬁlgrastim for
her low white blood cell count. She stayed in the hospital for ﬁfteen
days where she was followed with labs to monitor infection and HCG
Table 2
Admission labs and vitals on 2/3/14.
Labs Vitals
WBC 1.6 × 109 Temperature 38.6 °C
ANC 288 × 106 Heart rate 130 beats per minute
Hb 10.1 Blood pressure 140/80 mm Hg
Hct 0.295 Oxygen saturation 98% on room air
PLT 98
K 3.3
Table 1
HCG levels in IU/L.
12/12/13 60,638
12/25/13 100,606
12/27/13 (prior to D&C) 115,795
1/19/13 (day 1 post op laparoscopy) 47,365
1/20/14 32,085
1/21/14 22,660
1/23/14 24,491
1/26/14 38,250
1/30/14 40,610
2/07/14 40,610
2/17/14 9 (Post op liver surgery and start of MAC) 2764
2/23/14 1817
3/3/14 1702
3/8/14 182
Table 4
Admission labs for 3/8/14 admission.
WBC 2.4
Hb 9.5
Hct 0.274
PLT 81
ANC 288
Na 134
K 2.7
Cl 101
BUN 0.09
Cr 0.006
Ca 0.09
ALT 46
AST 15
Total Bili 0.018
Alk Phos 171
Table 5
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her antibiotic was discontinued. During her stay, she had nausea,
vomiting, diarrhea, and intermittent atrial ﬁbrillation due her refusing
potassium supplements. She also underwent her second round of che-
motherapy with MAC and was then discharged with plans to follow-
up in three days and to continue future chemotherapy treatments as
an outpatient.
On follow-up the patient had stomatitis of the mouth and felt weak.
Oxycodone andMagicmouthwashwere given for her pain and a follow-
up appointment was scheduled in a week. Five days later, on 3/8/14, at
the scheduled appointment, the patient presented for MAC round three
and was found to be tachycardic (with a heart rate of 140 beats per min
(BPM)). She was sent to the ER where her heart rate decreased to
118 BPM and labs were drawn (Table 4). She was admitted to have
her potassium replaced and to be given ﬁlgrastim for her low white
blood cell count and was then found to have a fever N 39.4 °C, likely
due to neutropenia. She was discharged after four days and told to fol-
low-up the next day. Prior to discharge the HCG was found to be
182 IU/L and the patient was told that chemotherapy would have to
continue for three rounds after the HCG reached zero. The patient suc-
cessfully had her HCG return to zero following a total of seven rounds
of MAC treatment.Normal lab values with abbreviations.
Lab name Normal value/range
White blood cell (WBC) 3.7–10.6 × 109/L
Hemoglobin (Hb) 110–140.9 g/L
Hematocrit (Hct) 0.36–0.46 proportion of 1.0
Absolute neutrophil count (ANC) N2000 × 106/L
Platelet (PLT) 141–359 × 109/L
Alanine aminotransferase (ALT) 0–32 IU/L
Aspartate aminotransferase (AST) 0–40 IU/L
Bilirubin total 0–0.012 g/L
Alkaline phosphatase (Alk Phos) 25–150 IU/L4. Discussion
The patient in this case study represents the common age, race, and
socioeconomic status in which complete mole occurs and subsequent
choriocarcinoma develops [1,8,13]. Approximately 70% of minority
women fail to comply with post-molar surveillance despite being
counseled on possiblemortality [10]. Living N20miles from the doctor's
location is considered a main culprit to making and keepingTable 3
Labs during 2/3–2/28/14 hospital admission.
HCG 2764 on 2/17/14
1817 on 2/23/14
ANC 2.7 × 1010 on 2/19/14appointments [10]. Because of the noncompliance rate, the Depo-
Provera shot is recommended for post-molar contraception in this pop-
ulation [6]. Even though the incidence of choriocarcinoma has de-
creased since the 1970s, it is still a possible outcome of complete
molar pregnancy so it is important to continue to inform the patient
of this possibility [8]. The patient in this case study did not follow-up
after her D&C, which conﬁrms what past research has shown based on
her race and socioeconomic status [1,8,13]. It is possible that if caught
earlier this patient would not have had metastasis to her liver or that
it would not have spread as much leading to a shorter duration of che-
motherapy although a molar pregnancy can metastasize both before
and after evacuation [1].
Further research is needed to determine if a uterine perforation dur-
ing D&C causes an increased incidence of metastatic choriocarcinoma
since studies in this area are lacking. In addition, research into how to
get a higher rate of compliance in patients with low socioeconomic sta-
tus is needed.5. Conclusion
Complete molar pregnancy is quite rare, but due to the adverse out-
comes that can occur, it is vital that it be found as early as possible. Doc-
tors must realize that the patient may not present with the symptoms
typically expected (large uterus, hyperthyroidism, etc.). If at any time
there are any signs that cause concern, especially in early pregnancy be-
fore a normal viable pregnancy has been conﬁrmed, an US and HCG
level should be performed. It is vital that once a complete molar preg-
nancy is conﬁrmed that it is removed and the patient is monitored to
ensure no subsequent complications. Any ensuing problems must beSodium (Na) 134–144 mmol/L
Potassium (K) 3.5–5.2 mmol/L
Chloride (Cl) 97–108 mmol/L
Calcium (Ca) 0.087–0.102 g/L
Blood urea nitrogen (BUN) 0.06–0.20 g/L
Creatinine (Cr) 0.0057–0.01 g/L
Glucose 3.9–6.1 mmol/L
β-Human chorionic gonadotropin (HCG) 0 non-pregnant IU/L
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still needed.
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